{
  "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
  "docSlug": "63ec8e773c9b43e7b033b64167026114",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 52,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses bar charts to compare IMX-110 performance against standard drugs like Trabectedin and a 4-drug combination.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/31",
  "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
  "deckJsonHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c.json",
  "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "chart",
      "text": "IMX-110 Demonstrated Response Rate Better than Standard of Care",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0c9089f-d195-4be3-b132-8bf11b288abb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.55,
        "y": 0.15
      },
      "kind": "chart",
      "text": "IMX-110 +anti-PD-1 Potential Survival Benefit Better than Comparable Median Survival",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc9cbfa9-0cb5-4019-8de2-a273fcf25e50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.05,
        "y": 0.00115
      },
      "kind": "chart",
      "text": "IMX-110 Demonstrated Improved Survival",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e20a431f-fa2f-456f-8642-2ccb2d0bf04a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.28,
        "y": 0.25
      },
      "kind": "list",
      "text": "In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs. One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "057618a3-2702-4559-93ea-ddf7febc546a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.28,
        "y": 0.6
      },
      "kind": "list",
      "text": "IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mice study.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d58f24f-a640-408e-8992-4840423e8a70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.75,
        "y": 0.35
      },
      "kind": "list",
      "text": "IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model. Historically, 42-days is the median survival produced by a 4-drug combination.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a64176f7-fb28-4615-88e8-9b32a3c3830a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7114170f-bbd5-44e1-8208-bb9e34433e16",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "IMX-110 Preclinical Data Provides Translational Rationale & PD-1 Combination Rationale",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdc8c06d-e11c-4ddd-b3a4-bfbfc4c26db3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}